Skip to content

Change in AR at other companies

Merck & Co. logo
Merck & Co.MRK
$272.5M+347%
Amgen logo
AmgenAMGN
-$413M-132%
Glaukos logo
GlaukosGKOS
$12.46M+1.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$6.3M+12.1%
Regenxbio logo
RegenxbioRGNX
-$18.25M-1,061%

Other financials

Income statement

See full
Revenue$3.6B+19.0%
Operating income$642.9M+8.7%
Net income$727.2M-10.1%
EPS (diluted)$6.75-7.2%

Balance sheet

See full
Cash & equivalents$3.0B-4.0%
Total debt$2.7B+0.1%
Total equity$31.4B+6.9%
Total assets$40.9B+8.9%

Cash flow

See full
Operating cash flow$1.1B+3.2%
CapEx$230.6M+0.6%
Free cash flow$848.3M+4.0%

Valuation

See full
Market cap$65.37B+21.9%
Enterprise value$65.11B+20.0%
P/E14.8×+2.8×
P/S4.4×+0.6×

Profitability

See full
Gross margin93.9%
Operating margin24.3%-2.9pp
Net margin29.6%-2.3pp
FCF margin27.6%+5.5pp

Returns & leverage

See full
Return on equity14.5%-1.4pp
Debt / equity0.1×0.0×
Current ratio3.6×-1.4×

Where this comes from

Reported directly by Regeneron Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regeneron Pharmaceuticals's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Regeneron Pharmaceuticals's change in AR?
Regeneron Pharmaceuticals (REGN) reported change in AR of -$1.2M in Q1 2026.
How has Regeneron Pharmaceuticals's change in AR changed year-over-year?
Regeneron Pharmaceuticals's change in AR increased by 99.8% year-over-year, from -$657.8M to -$1.2M.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.